Drug | EC50 [Ke] | Emax |
---|---|---|
nM | % | |
Experiment 1 ([3H]MPP+)a | ||
d-Amph | 5.8 ± 0.4 | 102 ± 2 |
+ SoRI-9804 (2.0 μM) | 8.3 ± 1.0 | 86 ± 2* |
+ SoRI-9804 (10 μM) | 11.5 ± 0.4 | 73 ± 0.5* |
+ cocaine (2.8 μM) | 82 ± 9* [0.21 μM] | 102 ± 2 |
Experiment 2 (Fig. 4), [3H]DA) | ||
d-Amph | 17 ± 3 | 108 ± 5 |
+ SoRI-9804 (2.0 μM) | 18 ± 2 | 94 ± 2* |
+ SoRI-9804 (10 μM) | 17 ± 3 | 88 ± 3* |
+ SoRI-9804 (50 μM) | 20 ± 3 | 90 ± 2* |
+ indatraline (10 nM) | 120 ± 21* [1.6 nM] | 104 ± 4 |
Experiment 3 ([3H]MPP+)a | ||
d-Amph | 6.5 ± 0.3 | 103 ± 1 |
+ SoRI-20040 (2.0 μM) | 11.6 ± 1.0 | 78 ± 2* |
+ SoRI-20040 (10 μM) | 15.7 ± 2.5* | 60 ± 2* |
+ indatraline (66 nM) | 116 ± 14* [3.9 nM] | 101 ± 3 |
Experiment 4 (Fig. 3), [3H]DA) | ||
d-Amph | 15 ± 2 | 107 ± 4 |
+ SoRI-20040 (2.0 μM) | 23 ± 5 | 89 ± 3* |
+ SoRI-20040 (10 μM) | 20 ± 3 | 81 ± 2* |
+ SoRI-20040 (50 μM) | 27 ± 68 | 79 ± 3* |
+ cocaine (2.8 μM) | 200 ± 39* [0.23 μM] | 103 ± 4 |